Testosterone Enanthate Muscle Preservation Strategies: A Clinical Guide

Is Muscle Preservation an Approved Use of Testosterone Enanthate?

No. Testosterone enanthate injection is indicated for replacement therapy when the body does not make enough testosterone — primary hypogonadism from testicular failure, or hypogonadotropic hypogonadism from pituitary or hypothalamic causes [5]. The FDA states that none of the approved testosterone products is approved for men with low testosterone who lack an associated medical condition [8]. The enanthate label describes effects on muscle and protein metabolism, but does not list muscle preservation as an approved use [5].

The label also states that safety and efficacy of testosterone enanthate in men with age-related hypogonadism have not been established [5]. FDA asked sponsors in June 2026 to remove that limitation of use, but the enanthate label still carries the older text, so the change is a request rather than a finished label revision [8][5].

What the Dose-Response Data Show

A 20-week study measured muscle responses in 61 healthy men aged 18 to 35 [2]. The men first received a long-acting GnRH agonist to shut off their own testosterone, then weekly enanthate injections of 25, 50, 125, 300 or 600 mg [2]. Nadir testosterone was 234, 289, 695, 1,344 and 2,435 ng/dL at those doses [2]. Vastus lateralis volume fell 4 mL at 25 mg and rose 7, 15, 32 and 48 mL at the higher doses [2]. Cross-sectional area of both type I and type II fibers changed with dose, and the number of myonuclei per fiber rose significantly at 300 and 600 mg [2].

That is a dose-response curve measured at the muscle, not a clinical strategy for preserving muscle in a hypogonadal man. The men were healthy and their own testosterone production was suppressed for the experiment [2].

The 1996 Trial: Testosterone Alone Versus Testosterone Plus Training

The training trial randomized 43 healthy men to four groups: placebo with no exercise, testosterone with no exercise, placebo plus exercise, and testosterone plus exercise [1]. Treatment was 600 mg of testosterone enanthate weekly for 10 weeks, and the exercise groups lifted three times a week [1].

In the no-exercise groups, testosterone beat placebo on triceps area (424 vs -81 square millimeters), quadriceps area (607 vs -131 square millimeters), bench press (9 vs -1 kg) and squat (16 vs 3 kg) [1]. The men who received testosterone and trained had greater increases in fat-free mass (6.1 kg), triceps area (501 square millimeters), quadriceps area (1,174 square millimeters), bench press (22 kg) and squat (38 kg) than either no-exercise group. The report gives the 6.1 kg figure for the combined group and states it exceeded both no-exercise groups; it does not report a separate fat-free mass number for testosterone alone [1].

Both trials used conditions that go beyond ordinary replacement therapy, and neither measured long-term muscle preservation in men with hypogonadism.

What a One-Year Testosterone Trial Found

The Testosterone Trials assigned 790 men aged 65 or older with a serum testosterone below 275 ng/dL and symptoms suggesting hypoandrogenism to testosterone gel or placebo gel for one year [9]. Treatment raised serum testosterone to the mid-normal range for men aged 19 to 40 [9].

Sexual activity, sexual desire and erectile function all improved significantly. The share of men who increased their 6-minute walking distance by at least 50 meters did not differ significantly within the Physical Function Trial, but did when men in all three trials were pooled, 20.5% versus 12.6% (P=0.003). Testosterone had no significant benefit on vitality. Adverse event rates were similar between groups, and the authors stated the number of participants was too few to draw conclusions about the risks of treatment [9]. This trial used gel, not injections.

What Does Resistance Training Add?

The training side has its own evidence in older adults. A Cochrane review of 121 trials with 6,700 participants found that progressive resistance training, usually performed two to three times a week at high intensity, had a large effect on muscle strength (standardized mean difference 0.84, 95% CI 0.67 to 1.00) [3]. Adverse events were poorly recorded across trials, but musculoskeletal complaints such as joint pain and muscle soreness were reported in many studies that monitored for them, and serious adverse events were rare [3].

Protein Intake: Where the Gains Level Off

A meta-analysis of 49 randomized trials with 1,863 participants found that protein supplementation increased fat-free mass by 0.30 kg (95% CI 0.09 to 0.52) and one-repetition-maximum strength by 2.49 kg (95% CI 0.64 to 4.33) during prolonged resistance training, and that the effect on fat-free mass shrank with increasing age [4]. Protein intakes above about 1.62 g/kg/day produced no further training-induced gain in fat-free mass [4].

The enanthate label's pharmacology section makes a related point: androgens have been reported to increase protein anabolism and decrease protein catabolism, but nitrogen balance improves only when calorie and protein intake are sufficient [5]. A review of whey protein describes whey as high in essential, branched-chain and leucine amino acids and rapidly digested, reports that it stimulates muscle protein synthesis more than casein or soy, and notes that higher-protein diets spare muscle mass during caloric restriction and blunt the age-related loss of muscle [10].

Hematocrit: The Monitoring That Interrupts Therapy

Raising testosterone raises red cell mass. A network meta-analysis of 29 placebo-controlled randomized trials (3,393 men) found mean hematocrit rose 4.0% (95% CI 2.9 to 5.1) with intramuscular enanthate or cypionate, 3.0% with gel and 1.4% with patch [6]. A retrospective review of 178 hypogonadal men followed for three years found hematocrit above 50% in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets. The injection group was younger (mean 42.5 vs 54.1 years) and started with higher baseline hematocrit, and the study was not randomized [11].

Reviews put the risk in context: men on testosterone replacement had a 315% greater risk of erythrocytosis defined as hematocrit above 0.52 than controls, and short-acting injectable formulations have the highest incidence, although the link between erythrocytosis and venous thromboembolism remains inconclusive [12][13].

Blood Pressure

FDA's 2025 labeling action says ambulatory blood pressure studies confirmed an increase in blood pressure with all testosterone products, class-wide, and required a new or updated blood pressure warning across products [14]. The enanthate label states that testosterone can increase blood pressure, which can increase cardiovascular risk over time, that blood pressure should be monitored periodically in men using testosterone products, and that the products are not recommended in patients with uncontrolled hypertension [5].

Fertility and the Body's Own Testosterone Production

Exogenous testosterone inhibits pituitary luteinizing hormone through feedback, and oligospermia may occur at high dosages [5]. Recovery data come mostly from other populations. An integrated analysis of 30 studies of 1,549 healthy men using hormonal contraception found the median time for sperm concentration to return to 20 million/mL was 3.4 months; 67% recovered within 6 months, 90% within 12, 96% within 16 and 100% within 24 [15]. In 66 men treated for infertility after testosterone use, 70% reached a total motile count above 5 million within 12 months of stopping testosterone and starting high-dose hCG plus a selective estrogen receptor modulator. Only 64.8% of azoospermic men did versus 91.7% of cryptozoospermic men, and older age and longer testosterone use predicted slower recovery [16].

The Endocrine Society guideline recommends against starting testosterone therapy in men planning fertility in the near term, and recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk during the first year [17].

Labeled Dosing

The labeled intramuscular regimen is 50 to 400 mg every 2 to 4 weeks, with total doses above 400 mg per month not required and injections more often than every 2 weeks rarely indicated [5].

Sport and Legal Status

Testosterone enanthate is a Schedule III controlled substance in the US [5]. WADA's 2026 Prohibited List places anabolic androgenic steroids, including testosterone, in category S1 and prohibits them at all times, in and out of competition. A prescription does not make testosterone permitted in WADA-governed sport; an athlete needs a Therapeutic Use Exemption [7].